Skip to main navigation
Skip to search
Skip to main content
Sort by
Keyphrases
Hematopoietic Stem Cell Transplant Recipients
44%
Cytomegalovirus Infection
39%
Hematopoietic Cell Transplantation
38%
Hematological Malignancies
34%
Cytomegalovirus
31%
Allogeneic Hematopoietic Stem Cell Transplantation (allo-HSCT)
24%
COVID-19
23%
Patients with Cancer
23%
Respiratory Syncytial Virus
22%
Cancer Patients
21%
Cell Therapy
21%
Letermovir
16%
Lower Respiratory Tract Infection
15%
Respiratory Syncytial Virus Infection
14%
Transplantation Therapy
14%
95% Confidence Interval
14%
Leukemia
14%
In Cancer
13%
Immunocompromised Patients
13%
Hematopoietic Stem Cell Transplant
13%
Risk Factors
12%
Respiratory Viral Infection
12%
Comprehensive Cancer Center
12%
American Society
11%
Hematopoietic Stem Cell Transplantation
11%
Allogeneic Hematopoietic Cell Transplant Recipients
11%
Infectious Diseases
10%
Pneumonia
10%
Cytomegalovirus Disease
10%
Patients with Hematological Malignancies
10%
Ribavirin
9%
Cancer Center
9%
Clinically Significant
9%
Chimeric Antigen Receptor T Cells (CAR-T)
8%
Clostridium Difficile Infection
8%
Neutropenia
8%
Antiretroviral Therapy
7%
Hazard Ratio
7%
Maribavir
7%
Frequently Asked Questions
7%
Vancomycin-resistant Enterococcus Faecium (VREfm)
7%
Upper Respiratory Tract Infection
6%
Graft-versus-host Disease (GvHD)
6%
Placebo
6%
High Risk
6%
Post-transplant Cyclophosphamide (PTCy)
6%
Influenza
6%
Lymphoma
6%
Cytomegalovirus Prophylaxis
6%
Brincidofovir
6%
Immunology and Microbiology
Infection
100%
Infectious Disease
99%
Hematopoietic Cell
80%
Cytomegalovirus
38%
Cell Transplantation
34%
Cytomegalovirus Infection
27%
Human respiratory syncytial virus
26%
Viral Disease
23%
Lower Respiratory Tract
16%
COVID-19
15%
Hematopoietic Stem Cell Transplantation
15%
Respiratory Syncytial Virus Infection
13%
Graft-Versus-Host Disease
11%
Stem Cell Transplant
9%
Influenza
8%
Morbidity
7%
Immunocompromised Patient
7%
BK Virus
7%
Vancomycin-Resistant Enterococcus
7%
Chimeric Antigen Receptor T-Cell Therapy
7%
Ribavirin
6%
Antibody Response
6%
Immunodeficiency
6%
Cyclophosphamide
6%
Respiratory Virus
6%
Palivizumab
5%
Virus
5%
Upper Respiratory Tract
5%
Overall Survival
5%
Viral Load
5%
All Cause Mortality
5%
Adoptive Immunity
5%
Medicine and Dentistry
Infection
40%
Malignant Neoplasm
37%
Hematopoietic Cell
36%
Cell Transplantation
25%
Hematologic Malignancy
25%
COVID-19
21%
Cell Therapy
19%
Cytomegalovirus Infection
18%
Cytomegalovirus
18%
Immunocompromised Patient
12%
Hematopoietic Stem Cell Transplantation
12%
Virus Infection
11%
Viral Respiratory Tract Infection
9%
Pneumonia
9%
Leukemia
9%
Infectious Disease
9%
Morbidity
7%
Diseases
6%
Antiinfective Agent
6%
Infection Control
6%
Systematic Review
6%
Virus
6%
Case-Control Study
5%
Methicillin Resistant Staphylococcus Aureus
5%
Pathogen
5%
Graft Versus Host Reaction
5%
Oral
5%
